CURE

Genetic Discovery Explains Drug Resistance in Breast Cancer

Resistant cells demonstrated global decreases in DNA accessibility with localized opening at resistance-driving loci, ...
Medscape

Prevalence and Outcomes of Breast Milk Expressing in Women With Healthy Term Infants

Considering the paucity of discussion in the literature, it appears that the implications of expressing on maternal mental health warrants attention. Identify relationships between breast pump use and ...
ascopubs.org

Loss of Her-2 expression after neo-adjuvant therapy with dual anti-Her-2 agents (Pertuzumab/Herceptin) with chemotherapy in locally advanced Her-2 positive breast cancer.

Prognostic factors impacting survival in early HER2-positive breast cancer (BC): Results from a 1,142 patients database study. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I.
ascopubs.org

Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast ...

PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline ...
Cure Today

Gene Expression Testing and Targeted Therapies in Breast Cancer Care

Gene expression testing, such as Oncotype DX, aids in chemotherapy decisions for hormone receptor-positive breast cancer, though challenges exist for premenopausal patients with scores under 25.

Novel biomarker predicts chemotherapy response in triple-negative breast cancer

Researchers at The University of Texas MD Anderson Cancer Center have developed a new computational approach designed to ...
Business Wire

OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

ROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic ...